Drug Repurposing
Drug repurposing is the development of existing drugs for new uses: given that 9 in 10 drugs that enter drug development are never marketed and therefore represent wasted effort, it is an attractive as well as inherently more efficient process. Three repurposed drugs can be brought to market for the same cost as one new chemical entity; and they can also be identified more quickly, an important benefit for patients whose diseases are progressing faster than therapeutic innovation. But repurposing also requires a fresh look at configuring pharmaceutical R&D, considering clinical, regulatory and patent issues much earlier than would otherwise be the case; a holistic gedanken experiment almost needs to be undertaken at the very start of any repurposing development. In addition to new ways of thinking, the discovery of repurposing opportunities can take advantage of artificial intelligence techniques to match the perfect new use for an existing drug. And while repurposing of medicines has been in the mind of every doctor since Hypocrates, modern clinical practice will simply have to adapt to new repurposing techniques in an age where the number of known diseases is increasing much faster than the healthcare dollars available.
Drug Repurposing, The Royal Society of Chemistry, 2022.
Download citation file:
Digital access
Print format
Table of contents
-
Chapter 1: Introduction and Historical Overview of Drug Repurposing Opportunitiesp1-13ByS. PushpakomS. PushpakomMRC Centre for Drug Safety Science and The Wolfson Centre for Personalised Medicine, Department of Pharmacology & Therapeutics, University of LiverpoolLiverpoolUK[email protected]Search for other works by this author on:
-
Chapter 2: Role of Academia: Drug Repurposing to Induce Autophagy for Treatment of Neurodegenerative Diseasesp14-23ByM. Fernandez-Estevez;M. Fernandez-EstevezDepartment of Medical Genetics, Cambridge Institute for Medical Research, University of CambridgeCambridgeUK[email protected]UK Dementia Research InstituteCambridgeUKSearch for other works by this author on:L. Wrobel;L. WrobelDepartment of Medical Genetics, Cambridge Institute for Medical Research, University of CambridgeCambridgeUK[email protected]UK Dementia Research InstituteCambridgeUKSearch for other works by this author on:D. C. RubinszteinD. C. RubinszteinDepartment of Medical Genetics, Cambridge Institute for Medical Research, University of CambridgeCambridgeUK[email protected]UK Dementia Research InstituteCambridgeUKSearch for other works by this author on:
-
Chapter 3: The Role of Clinical Medicinep24-51ByAntony A. Cooper;Antony A. CooperGarvan Institute384 Victoria StDarlinghurst NSW 2010AustraliaSt Vincent's Clinical School, UNSW SydneySydneyAustraliaSearch for other works by this author on:Simon R. W. StottSimon R. W. StottSearch for other works by this author on:
-
Chapter 4: Role of Industryp52-73ByD. J. Hayes;D. J. HayesDavid Hayes, Emerging Innovations, Discovery Sciences, R&DAstraZenecaWalthamUSASearch for other works by this author on:K. J. EscottK. J. EscottK. Jane Escott, Business Development & Licensing, BioPharmaceuticals R&DAstraZenecaCambridgeUK[email protected]Search for other works by this author on:
-
Chapter 5: Collaboration Models for Repurposingp74-100ByBruce BloomBruce BloomSearch for other works by this author on:
-
Chapter 6: Screening Technologiesp101-128ByF. SheinermanF. SheinermannPharmakon LLCNew YorkNYUSASearch for other works by this author on:
-
Chapter 7: Cheminformatics Data Mining and Modeling for Drug Repurposingp129-146ByS. Avram;S. AvramDepartment of Computational Chemistry, “Coriolan Dragulescu” Institute of Chemistry24 Mihai Viteazu BlvdTimişoaraTimiş300223RomâniaSearch for other works by this author on:R. Curpan;R. CurpanDepartment of Computational Chemistry, “Coriolan Dragulescu” Institute of Chemistry24 Mihai Viteazu BlvdTimişoaraTimiş300223RomâniaSearch for other works by this author on:T. I. OpreaT. I. OpreaTranslational Informatics Division, Department of Internal Medicine, University of New Mexico School of MedicineAlbuquerqueNew Mexico 87131USA[email protected]Search for other works by this author on:
-
Chapter 8: Using Artificial Intelligence for Drug Repurposingp147-172ByA. BenderA. BenderCentre for Molecular Informatics, Department of Chemistry, University of CambridgeUnited Kingdom[email protected]Search for other works by this author on:
-
Chapter 9: Field Discoveries (Case Reports)p173-195ByMoshe RogosnitzkyMoshe RogosnitzkySearch for other works by this author on:
-
Chapter 10: Preclinical. A Repurposed Novel Lyn Kinase Activator, MLR-1023, is a Model Example of Pharmacological Pleiotropyp196-220ByChristopher A. LipinskiChristopher A. LipinskiSearch for other works by this author on:
-
Chapter 11: Harnessing the Potential of Early Access: Advancing Timely Patient Access to Innovative Medicines in a Sustainable Wayp221-243ByIngmar de Gooijer;Ingmar de GooijermyTomorrows, Director Public PolicyAnthony Fokkerweg 611059 CP AmsterdamThe Netherlands[email protected]Search for other works by this author on:Ronald BrusRonald BrusSearch for other works by this author on:
-
Chapter 12: Adapting Payers’ and Producers’ Incentives to Drug Repurposingp244-263ByB. Handelin;B. HandelinAudacity Therapeutics PaoliPA 19301USASearch for other works by this author on:D. CavallaD. CavallaNumedicus LtdCambridge CB1 2DXUKSearch for other works by this author on:
-
Chapter 13: Intellectual Property Considerationsp264-279ByHermann MuckeHermann MuckeSearch for other works by this author on:
-
Chapter 14: Regulatory Considerations and Strategies for Drug Repositioningp280-300ByKenneth V. PhelpsKenneth V. PhelpsSearch for other works by this author on:
-
Chapter 15: Future Perspectives in Drug Repurposingp301-319ByDavid CavallaDavid CavallaSearch for other works by this author on:
Spotlight
Advertisement
Advertisement
